Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1948 1
1965 1
1966 2
1968 2
1970 1
1972 1
1974 3
1975 7
1976 8
1977 11
1978 17
1979 11
1980 15
1981 11
1982 21
1983 13
1984 7
1985 10
1986 11
1987 5
1988 8
1989 4
1990 13
1991 17
1992 9
1993 12
1994 11
1995 14
1996 15
1997 8
1998 18
1999 10
2000 9
2001 22
2002 18
2003 21
2004 13
2005 20
2006 22
2007 16
2008 25
2009 14
2010 17
2011 22
2012 25
2013 17
2014 28
2015 29
2016 17
2017 8
2018 10
2019 7
2020 0
Text availability
Article attribute
Article type
Publication date

Search Results

617 results
Results by year
Filters applied: . Clear all
Page 1
Cutaneous T-cell lymphoma: 2017 update on diagnosis, risk-stratification, and management.
Wilcox RA. Am J Hematol 2017 - Review. PMID 28872191 Free article.
DISEASE OVERVIEW: Cutaneous T-cell lymphomas are a heterogenous group of T-cell lymphoproliferative disorders involving the skin, the majority of which may be classified as Mycosis Fungoides (MF) or Sézary Syndrome (SS). ...In highly-selected patients, allogeneic stem-cell transplantation may be considered, as this may be curative in some patients....
DISEASE OVERVIEW: Cutaneous T-cell lymphomas are a heterogenous group of T-cell lymphoproliferative disorders involving …
Primary T Cells from Cutaneous T-cell Lymphoma Skin Explants Display an Exhausted Immune Checkpoint Profile.
Querfeld C, et al. Cancer Immunol Res 2018. PMID 29895574 Free PMC article.
Cutaneous T-cell lymphoma (CTCL) develops from clonally expanded CD4(+) T cells in a background of chronic inflammation. Although dendritic cells (DCs) stimulate T cells and are present in skin, cutaneous T cells in CTCL do not respond with effective antitumor immunity. ...CTCL populations also contained more T cells expressing the inducible T-cell costimulator (ICOS), a marker of T-cell activation. ...
Cutaneous T-cell lymphoma (CTCL) develops from clonally expanded CD4(+) T cells in a background of chronic inflammation. Altho
Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers.
Jawed SI, et al. J Am Acad Dermatol 2014 - Review. PMID 24438969
Mycosis fungoides (MF) and Sézary syndrome (SS) comprise approximately 53% of cutaneous lymphomas. Both MF and SS may clinically and histologically mimic benign skin conditions, posing a diagnostic challenge to the dermatologist. ...In addition, recent studies have also suggested that MF and SS arise from distinct memory T cell subsets and advanced/erythrodermic MF and SS may be distinguished by identification of certain molecules, including Programmed-Death-1....
Mycosis fungoides (MF) and Sézary syndrome (SS) comprise approximately 53% of cutaneous lymphomas. Both MF and SS may clinically and …
Cutaneous T-cell lymphoma: 2016 update on diagnosis, risk-stratification, and management.
Wilcox RA. Am J Hematol 2016 - Review. PMID 26607183 Free PMC article.
DISEASE OVERVIEW: Cutaneous T-cell lymphomas are a heterogenous group of T-cell lymphoproliferative disorders involving the skin, the majority of which may be classified as Mycosis Fungoides (MF) or Sézary Syndrome (SS). ...In highly-selected patients, allogeneic stem-cell transplantation may be considered, as this may be curative in some patients....
DISEASE OVERVIEW: Cutaneous T-cell lymphomas are a heterogenous group of T-cell lymphoproliferative disorders involving …
Expression of T-follicular helper markers in sequential biopsies of progressive mycosis fungoides and other primary cutaneous T-cell lymphomas.
Bosisio FM and Cerroni L. Am J Dermatopathol 2015. PMID 25406852
T-follicular helper (Tfh) lymphocytes represent the neoplastic cells of angioimmunoblastic T-cell lymphoma and have been observed also in several cutaneous T-cell lymphomas (CTCLs) and extracutaneous T-cell lymphomas, including peripheral T-cell lymphoma, not otherwise specified, mycosis fungoides (MF), cutaneous CD4 small/medium T-cell lymphoma (CD4SMTCL), and Sezary syndrome. We studied a large number of different types of primary CTCL for expression of Tfh markers, including 36 biopsies from 21 patients with MF (with sequential biopsies from patch stage and tumor stage of 15 patients), 13 patients with CD4SMTCL, 9 with lymphomatoid papulosis, 11 with cutaneous anaplastic large cell lymphoma (cALCL), 2 with cutaneous γ/δ T-cell lymphoma, 8 with subcutaneous panniculitis-like T-cell lymphoma, 3 with cutaneous aggressive epidermotropic CD8 cytotoxic T-cell lymphoma, 6 with cutaneous peripheral T-cell lymphoma, not otherwise specified, and 1 with Sezary syndrome. ...
T-follicular helper (Tfh) lymphocytes represent the neoplastic cells of angioimmunoblastic T-cell lymphoma and have been observed als …
Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma.
Duvic M, et al. Blood 2015 - Clinical Trial. PMID 25605368 Free PMC article.
This phase 1/2 study evaluated the efficacy of mogamulizumab, a defucosylated, humanized, anti-CC chemokine receptor 4 monoclonal antibody, in 41 pretreated patients with cutaneous T-cell lymphoma. ...Given the safety and efficacy of mogamulizumab, phase 3 investigation of mogamulizumab is warranted in cutaneous T-cell lymphoma patients. ...
This phase 1/2 study evaluated the efficacy of mogamulizumab, a defucosylated, humanized, anti-CC chemokine receptor 4 monoclonal antibody, …
Innovative Treatment Concepts for Cutaneous T-Cell Lymphoma Based on Microenvironment Modulation.
Leuchte K, et al. Oncol Res Treat 2017 - Review. PMID 28423378
Cutaneous T-cell lymphomas (CTCL) are a rare and biologically heterogeneous malignant entity comprising mycosis fungoides and Sézary syndrome as the most common subtypes. ...
Cutaneous T-cell lymphomas (CTCL) are a rare and biologically heterogeneous malignant entity comprising mycosis fungoides and
Extracorporeal photopheresis of cutaneous T-cell lymphoma is associated with reduction of peripheral CD4+ T lymphocytes.
Zouboulis CC, et al. Dermatology 1998 - Clinical Trial. PMID 9621137
BACKGROUND: Extracorporeal photopheresis (ECP) has been successfully introduced for the treatment of cutaneous T-cell lymphoma; however, the mechanism(s) of its action is (are) unknown. OBJECTIVE: To investigate the effects of ECP on the immune system of patients with cutaneous T-cell lymphoma. METHODS: Clinical response and changes of lymphocyte subpopulations in 20 patients with cutaneous T-cell lymphoma under ECP monotherapy or combined regimens were evaluated and compared after 3, 6 and 12 ECP cycles. ...
BACKGROUND: Extracorporeal photopheresis (ECP) has been successfully introduced for the treatment of cutaneous T-cell lymphoma …
617 results
Jump to page
Feedback